Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bailey

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Pathology|July 2, 2019
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapyClaire S Reader, Sabari Vallath, Colin W Steele, et al.
Gut|April 26, 2024
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDACFrancesca Lupo, Francesco Pezzini, Davide Pasini, et al.
Nature Communications|February 22, 2017
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancerAdrian Vallejo, Naiara Perurena, Elisabet Guruceaga, et al.
Nature Cancer|September 7, 2023
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDACXu Zhou, Jingyu An, Roma Kurilov, et al.
Nature Communications|December 1, 2018
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levelsDavid Novo, Nikki Heath, Louise Mitchell, et al.
Immunity|May 15, 2024
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancerFrancesco De Sanctis, Silvia Dusi, Simone Caligola, et al.
Nature Communications|August 25, 2023
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progressionPeter Bailey, Rachel A Ridgway, Patrizia Cammareri, et al.
Oncogene|August 13, 2022
Loss of FGFR4 promotes the malignant phenotype of PDACSabrina D'Agosto, Francesco Pezzini, Lisa Veghini, et al.
EMBO Molecular Medicine|June 17, 2015
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacyBryan W Miller, Jennifer P Morton, Mark Pinese, et al.
Gastroenterology|November 19, 2022
N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for ImmunotherapyJulia Krug, Gabriele Rodrian, Katja Petter, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Pathology|July 2, 2019
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapyClaire S Reader, Sabari Vallath, Colin W Steele, et al.
Gut|April 26, 2024
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDACFrancesca Lupo, Francesco Pezzini, Davide Pasini, et al.
Nature Communications|February 22, 2017
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancerAdrian Vallejo, Naiara Perurena, Elisabet Guruceaga, et al.
Nature Cancer|September 7, 2023
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDACXu Zhou, Jingyu An, Roma Kurilov, et al.
Nature Communications|December 1, 2018
Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levelsDavid Novo, Nikki Heath, Louise Mitchell, et al.
Immunity|May 15, 2024
Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancerFrancesco De Sanctis, Silvia Dusi, Simone Caligola, et al.
Nature Communications|August 25, 2023
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progressionPeter Bailey, Rachel A Ridgway, Patrizia Cammareri, et al.
Oncogene|August 13, 2022
Loss of FGFR4 promotes the malignant phenotype of PDACSabrina D'Agosto, Francesco Pezzini, Lisa Veghini, et al.
EMBO Molecular Medicine|June 17, 2015
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacyBryan W Miller, Jennifer P Morton, Mark Pinese, et al.
Gastroenterology|November 19, 2022
N-glycosylation Regulates Intrinsic IFN-γ Resistance in Colorectal Cancer: Implications for ImmunotherapyJulia Krug, Gabriele Rodrian, Katja Petter, et al.
Pageof 9